Trial Profile
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Rituximab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms COUP-1
- 27 Aug 2023 This trial has been completed in Austria, according to the European Clinical Trials Database record.
- 23 Aug 2023 Planned number of patients changed from 56 to 36.
- 23 Aug 2023 Status changed from recruiting to active, no longer recruiting.